<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3013">
  <stage>Registered</stage>
  <submitdate>21/10/2010</submitdate>
  <approvaldate>21/10/2010</approvaldate>
  <nctid>NCT01253681</nctid>
  <trial_identification>
    <studytitle>Study of AMG 386 in Combination With Paclitaxel and Carboplatin in Subjects With Ovarian Cancer</studytitle>
    <scientifictitle>A Phase 1b Open-Label, Multi-Center Study of AMG 386 in Combination With Paclitaxel and Carboplatin in Subjects With High-Risk Stage I and Stages II-IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>20090155</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Carcinoma</healthcondition>
    <healthcondition>Fallopian Tube Cancer</healthcondition>
    <healthcondition>Ovarian Cancer</healthcondition>
    <healthcondition>Primary Peritoneal Cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Ovarian and primary peritoneal</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Womb (Uterine or endometrial cancer)</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - AMG 386, paclitaxel and carboplatin

Experimental: AMG 386, paclitaxel and carboplatin - 15 mg/Kg AMG 386 IV (intravenous) weekly plus paclitaxel and carboplatin IV Q3W for 18 weeks, followed by 15mg/Kg AMG 386 IV (intravenous) weekly alone for an additional 18 months.


Treatment: drugs: AMG 386, paclitaxel and carboplatin
15 mg/Kg AMG 386 IV (intravenous) weekly plus paclitaxel and carboplatin IV Q3W for 18 weeks, followed by 15mg/Kg AMG 386 IV (intravenous) weekly alone for an additional 18 months.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To evaluate whether AMG 386 in combination with paclitaxel and carboplatin is safe and well tolerated in the first-line treatment of high-risk stage I and stages II-IV epithelial ovarian, primary peritoneal and fallopian tube cancers.</outcome>
      <timepoint>18 weeks of combination therapy</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To evaluate the pharmacokinetics (Cmax, AUC and Cmin) of AMG 386 in combination with carboplatin and paclitaxel</outcome>
      <timepoint>Week 1 until Week 7</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To estimate the incidence of anti-AMG 386 antibody formation</outcome>
      <timepoint>Week 1 until maximum of 1 year following first dose</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To evaluate the objective response rate (ORR) among subjects receiving AMG 386 in combination with carboplatin and paclitaxel</outcome>
      <timepoint>From date of first dose until the subject reaches End of Study. This will continue until 36 months after the last subject has been enrolled.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To evaluate the duration of response (DOR) among subjects receiving AMG 386 in combination with carboplatin and paclitaxel</outcome>
      <timepoint>From date of first dose until the subject reaches End of Study. This will continue until 36 months after the last subject has been enrolled.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To evaluate progression-free survival (PFS) among subjects receiving AMG 386 in combination with carboplatin and paclitaxel</outcome>
      <timepoint>From date of first dose until the subject reaches End of Study. This will continue until 36 months after the last subject has been enrolled.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To evaluate the number of participants with adverse events and clinical laboratory abnormalities</outcome>
      <timepoint>96 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To evaluate the effect of AMG 386 on the pharmacokinetics (Cmax, AUC and Cmin) of carboplatin and paclitaxel</outcome>
      <timepoint>Week 1 until Week 7</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Female subjects more than 18 years of age with newly diagnosed high-risk FIGO Stage I
             (grade 3, or aneuploid grade 1 or 2) or Stages II-IV epithelial ovarian, primary
             peritoneal and fallopian tube cancer with an indication for first-line treatment with
             paclitaxel and carboplatin x 6 cycles. Subjects with pseudomyxoma, mesothelioma,
             adenocarcinoma of unknown primary tumor, sarcoma, or neuroendocrine histology are
             excluded.

          -  Subjects with high-risk stage I, stage II, or stage IIIA-B must have had prior primary
             debulking surgery that occurred no less than 4 weeks, and no more than 12 weeks, prior
             to enrollment. Subjects must have recovered fully from surgery in the opinion of the
             investigator

          -  Subjects with Stage IIIC or IV disease who have not had primary debulking surgery must
             have planned interval debulking surgery following 3 cycles of AMG 386, paclitaxel and
             carboplatin

          -  Female 18 years of age or older at the time the written informed consent is obtained

          -  Subjects of child-bearing potential who have not undergone a bilateral
             salpingo-oophorectomy and are sexually active must consent to use an accepted and
             effective non-hormonal method of contraception (i.e, double barrier method (eg, condom
             plus diaphragm) from signing the informed consent through 6 months after last dose of
             study drug

          -  GOG Performance Status of 0 or 1

          -  Life expectancy = 3 months (per investigator opinion)

          -  Subject plans to begin protocol-directed therapy within 7 days from enrollment

          -  Adequate organ and hematological function as evidenced by the following laboratory
             studies prior to enrollment:

        Hematological function, as follows:

          -  Hemoglobin = 9 g/dL

          -  Absolute neutrophil count (ANC) = 1.5 x 10x9/L

          -  Platelet count = 100 x 10x9/L and = 850 x 10x9/L

          -  PTT or aPTT = 1.5 x ULN per institutional laboratory range and INR = 1.5

        Renal function, as follows:

          -  Urinary protein quantitative value of = 30 mg/dL in urinalysis or = 1+ on dipstick,
             unless quantitative protein is &lt; 1000 mg in a 24 hour urine sample

          -  Creatinine clearance &gt; 40 mL/min per 24-hr urine collection or calculated according to
             the Cockcroft-Gault formula

        Hepatic function, as follows:

          -  AST and ALT = 2.5 x ULN per institutional laboratory range (or = 5 x ULN if liver
             metastases are present)

          -  Total bilirubin = 1.5x institutions' ULN Nutritional

          -  Albumin = 2.8 g/dL</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Female</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Prior use of anticancer therapy or experimental therapy for epithelial ovarian,
             primary peritoneal or fallopian tube cancers

          -  Previous abdominal and/or pelvic external beam radiotherapy

          -  Subjects believed to be a higher than average risk of bowel perforation. This includes
             current symptoms of partial or complete bowel obstruction, recent (within 6 months)
             history of fistula or bowel perforation, subjects requiring total parenteral nutrition
             and continuous hydration

          -  History of arterial or venous thromboembolism within 12 months prior to enrollment

          -  History of clinically significant bleeding within 6 months prior to enrollment

          -  History of central nervous system metastasis

          -  Known active or ongoing infection (except uncomplicated urinary tract infection)
             within 14 days prior to enrollment

          -  Currently or previously treated with AMG 386, or other molecules that inhibit the
             angiopoietins or Tie2 receptor

          -  Current or within 30 days prior to enrollment treatment with immune modulators such as
             systemic cyclosporine or tacrolimus

          -  Prior myeloablative high-dose chemotherapy with allogeneic or autologous stem cell (or
             bone marrow) transplant

          -  Clinically significant cardiac disease within 12 months prior to enrollment, including
             myocardial infarction, unstable angina, grade 2 or greater peripheral vascular
             disease, cerebrovascular accident, transient ischemic attack, congestive heart
             failure, or arrhythmias not controlled by outpatient medication or placement of
             percutaneous transluminal coronary angioplasty/stent

          -  Uncontrolled hypertension as defined as diastolic blood pressure &gt; 90 mmHg OR systolic
             blood pressure &gt; 140 mmHg. The use of anti-hypertensive medications to control
             hypertension is permitted

          -  Subjects with a history of prior malignancy, except:

        Malignancy treated with curative intent and with no known active disease present for = 3
        years prior to enrollment and felt to be at low risk for recurrence by treating physician,
        Adequately treated non-melanomatous skin cancer or lentigo maligna without evidence of
        disease Adequately treated cervical carcinoma in situ without evidence of disease

          -  Major surgery within 28 days prior to enrollment or still recovering from prior
             surgery

          -  Minor surgical procedures, including placement of tunneled central venous access
             device, within 3 days prior to enrollment

          -  History of allergic reactions to bacterially-produced proteins

          -  Hypersensitivity to paclitaxel or drugs using the vehicle cremophor

          -  Pregnant (ie, positive beta-human chorionic gonadotropin test) or is breast feeding or
             planning to become pregnant within 6 months after the end of treatment

          -  Subject has known positive test(s) for human immunodeficiency virus (HIV) infection,
             hepatitis C virus, acute or chronic active hepatitis B infection

          -  Any condition which in the investigator's opinion makes the subject unsuitable for
             study participation

          -  Any uncontrolled concurrent illness or history of any medical condition that may
             interfere with the interpretation of the study results

          -  Non-healing wound, ulcer (including gastrointestinal) or fracture

          -  Subject has previously been enrolled onto this study

          -  Subject will not be available for follow-up assessment

          -  Subject has known sensitivity to any of the products to be administered during dosing

          -  Subject has any kind of disorder that compromises the ability of the subject to give
             written informed consent and/or to comply with study procedures</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/11/2010</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>27</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/01/2015</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Research Site - Footscray</hospital>
    <hospital>Research Site - Malvern</hospital>
    <hospital>Research Site - Parkville</hospital>
    <postcode>3011 - Footscray</postcode>
    <postcode>3144 - Malvern</postcode>
    <postcode>3052 - Parkville</postcode>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Brussels</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Bruxelles</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Leuven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Catalu√±a</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Amgen</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>To evaluate whether AMG 386 in combination with paclitaxel and carboplatin is safe and well
      tolerated in the first-line treatment of high-risk stage I and stages II-IV epithelial
      ovarian, primary peritoneal and fallopian tube cancers. The hypothesis is that AMG 386 in
      combination with carboplatin and paclitaxel is safe and well tolerated.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01253681</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>MD</name>
      <address>Amgen</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>